Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.05 | -0.01 |
| FCF Yield | -130.19% | -58.31% | 4.00% | -50.63% |
| EV / EBITDA | -0.22 | 0.41 | 44.97 | -0.37 |
| Quality | ||||
| ROIC | -58.29% | -93.53% | 25.44% | -185.79% |
| Gross Margin | 0.00% | 0.00% | 99.98% | 0.00% |
| Cash Conversion Ratio | 3.30 | 0.96 | 1.16 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,779,926.09% | 1,779,926.09% | 1,779,926.09% | -100.00% |
| Free Cash Flow Growth | -28.67% | -250.67% | 175.05% | 13.13% |
| Safety | ||||
| Net Debt / EBITDA | 2.02 | 2.01 | -10.25 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -57.78 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -169,830.00 | -96,300.00 | -27,675.00 |